Transforming Pathology: A New Era in RNA Analysis Partnership
Molecular Instruments (MI), a pioneer in innovative HCR™ Imaging technology, has announced an exciting partnership with Visiopharm. This collaboration represents a significant step forward in the field of precision pathology by integrating MI's clinical-grade HCR™ platform with Visiopharm’s Oncotopix® Discovery software.
Combining Forces for Enhanced Precision
The core strength of this partnership lies in the fusion of MI's leading HCR™ Pro RNA-ISH assay with Visiopharm's advanced AI-driven solutions. The collaboration allows researchers to utilize a deep learning approach for accurate imaging analysis of RNA-ISH assays. The HCR™ Pro RNA-ISH assay has set new benchmarks by enabling protease-free sample preparations while ensuring exceptional specificity and sensitivity in RNA detection.
Enhancing Clinical-Grade Assays
Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments, emphasizes the commitment of MI to elevate bioimaging assays to a clinical-grade standard that focuses on performance and accessibility. By joining forces with Visiopharm, both organizations are dedicated to delivering high-quality assays and robust analysis tools that empower pathologists and enhance clinical decision-making processes.
Transformational Tools for Researchers
The Oncotopix® Discovery software offers users the flexibility to intuitively explore complex tissue data and tailor analyses to meet their unique experimental requirements. Users can develop custom deep-learning algorithms that offer improved accuracy in segmenting cellular and nuclear structures, enhancing the quantification of RNA in complex tissue samples.
Revolutionizing the Analysis of Tissue Samples
Regan Baird, Senior Vice President of Commercial Strategy Deployment at Visiopharm, shares the company's vision of empowering researchers through advanced analytical tools that yield exceptional precision in image analysis. The synergy between MI's HCR™ technology and Visiopharm's software opens up new avenues for researchers, enabling them to achieve unprecedented levels of accuracy and efficiency in RNA-ISH analysis.
Advancing Research and Diagnostic Capabilities
The collaboration signifies a noteworthy advancement in research methodologies by combining high-performance RNA-ISH capabilities with sophisticated image analysis techniques. This integration facilitates breakthroughs in understanding gene expression and protein interactions, providing scientists with deeper insights into complex biological processes.
By streamlining the integration of innovative technologies, this partnership seeks to propel discoveries in translational medicine. Accurate comprehension of gene and protein expressions is vital, laying the groundwork for advancements in disease research and potential clinical applications.
About Molecular Instruments
Molecular Instruments develops and synthesizes molecular kits centered around the revolutionary HCR™ imaging platform. Their work supports various applications across academic research, drug development, synthetic biology, and clinical pathology. For further exploration of MI’s offerings, visit their official website.
About Visiopharm
Visiopharm stands out as a premier provider of AI-driven precision pathology software, promoting accurate data acquisition for tissue-based research. Their diagnostic tools are recognized within clinical applications, successfully deploying multiple IVDR-cleared algorithms for customers worldwide.
Frequently Asked Questions
What is the significance of the partnership between Molecular Instruments and Visiopharm?
This partnership enhances precision in RNA-ISH assays, allowing for advanced analysis techniques and improved data accuracy.
How does HCR™ Pro RNA-ISH assay benefit researchers?
The assay ensures protease-free sample preparation, along with unmatched specificity and sensitivity in RNA detection, thereby elevating research standards.
What capabilities does Oncotopix® Discovery software provide?
This software allows researchers to manipulate and analyze complex tissue data with customizable deep-learning algorithms for enhanced image analysis.
Why is clinical-grade standard important in pathology?
Clinical-grade standards ensure the reliability and accuracy of diagnostic tools, which are essential for effective patient care and research integrity.
How will this partnership impact future research?
The collaboration aims to drive discoveries in gene expression and protein interactions, advancing the field of translational medicine for more effective diagnostics.
